AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie pending Claims — Prescription Opioid State Lawsuits (cases)
Form 10-Q / 10-K Contingencies Note
Latest, Q2 2026
20
Period ended Jun 30, 2026
Change on a year earlier
-20.0%
25 in Q2 2025
History
24 quarters
Since Q2 2020
Sources
24
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pending Claims — Prescription Opioid State Lawsuits (cases) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 20 | -20.0% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 20 | -33.3% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 25 | -28.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 25 | -28.6% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 25 | -44.4% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 30 | -81.8% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 35 | -80.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 35 | -78.1% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 45 | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 165 | -38.9% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 175 | -35.2% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 160 | -43.7% | Form 10-Q (filed 2023-11-06) ↗ |
| Q1 2023 | Mar 31, 2023 | 270 | +5.1% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 270 | +7.6% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2022 | Sep 30, 2022 | 284 | -5.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 266 | -11.3% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 257 | -14.3% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 251 | -16.3% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 300 | +7.5% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 300 | +7.5% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 300 | – | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 300 | – | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 279 | – | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 279 | – | Form 10-Q (filed 2020-08-04) ↗ |
Cite this data
StockData. (2026). AbbVie Pending Claims — Prescription Opioid State Lawsuits (cases), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit_opioid_state
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.